Leiden University Scholarly Publications

Persistent URL of this record https://hdl.handle.net/1887/108933

In Collections

This item can be found in the following collections:

Verburg, F.A.; Stokkel, M.P.M.; Duren, C.; Verkooijen, R.B.T.; Mader, U.; Isselt, J.W. van; ... ; Luster, M. (2010)

No survival difference after successful I-131 ablation between patients with initially low-risk and high-risk differentiated thyroid cancer

Article / Letter to editor
To compare disease-specific survival and recurrence-free survival (RFS) after successful I-131 ablation in patients with differentiated thyroid carcinoma (DTC) between those defined before ablation as low-risk and those defined as high-risk according to the European Thyroid Association 2006 consensus statement. Retrospective data from three university hospitals were pooled. Of 2009 consecutive patients receiving ablation, 509 were identified as successfully ablated based on both undetectable stimulated serum thyroglobulin in the absence of antithyroglobulin antibodies and a negative diagnostic whole-body scan in a follow-up examination conducted 8.1 +/- 4.6 months after ablation. Of these 509 patients, 169 were defined as high-risk. After a mean follow-up of 81 +/- 64 months (range 4-306 months), only three patients had died of DTC, rendering assessment of disease-specific survival differences impossible. Of the 509 patients, 12 (2.4%) developed a recurrence a mean 35 months (range...Show moreTo compare disease-specific survival and recurrence-free survival (RFS) after successful I-131 ablation in patients with differentiated thyroid carcinoma (DTC) between those defined before ablation as low-risk and those defined as high-risk according to the European Thyroid Association 2006 consensus statement. Retrospective data from three university hospitals were pooled. Of 2009 consecutive patients receiving ablation, 509 were identified as successfully ablated based on both undetectable stimulated serum thyroglobulin in the absence of antithyroglobulin antibodies and a negative diagnostic whole-body scan in a follow-up examination conducted 8.1 +/- 4.6 months after ablation. Of these 509 patients, 169 were defined as high-risk. After a mean follow-up of 81 +/- 64 months (range 4-306 months), only three patients had died of DTC, rendering assessment of disease-specific survival differences impossible. Of the 509 patients, 12 (2.4%) developed a recurrence a mean 35 months (range 12-59 months) after ablation. RFS for the duration of follow-up was 96.6% according to the Kaplan-Meier method. RFS did not differ between high-risk and low-risk patients (p=0.68). RFS differed slightly but significantly between those with papillary and those with follicular thyroid carcinoma (p=0.03) and between those aged a parts per thousand currency sign45 years those aged > 45 years at diagnosis (p=0.018). After (near) total thyroidectomy and successful I-131 ablation, RFS does not differ between patients classified as high-risk and those classified as low-risk based on TNM stage at diagnosis. Consequently, the follow-up protocol should be determined on the basis of the result of initial treatment rather than on the initial tumour classification.Show less
I-131 Ablation Differentiated thyroid cancer Risk stratification Recurrence Survival Prognostic factors recombinant human thyrotropin radioiodine remnant ablation serum thyroglobulin stimulated serum hormone withdrawal follow-up carcinoma management tg perspective
All authors
Verburg, F.A.; Stokkel, M.P.M.; Duren, C.; Verkooijen, R.B.T.; Mader, U.; Isselt, J.W. van; Marlowe, R.J.; Smit, J.W.; Reiners, C.; Luster, M.
Date
2010-02-28
Journal
European Journal of Nuclear Medicine and Molecular Imaging
Volume
37
Issue
2
Pages
276 - 283
DOI
doi:10.1007/s00259-009-1315-6